ENDOCYTE INC Business Operations Contracts & Agreements
32 Contracts & Agreements
- Collaboration Agreements (1 contract)
- Marketing Agreements (30)
- Supply Agreements (1)
- Global Supply Agreement, dated as of July 5, 2018, between Endocyte, Inc. and ITG Isotope Technologies Garching GmbH (Filed With SEC on July 11, 2018)
- COLLABORATION, EXCLUSIVE LICENSE, AND COMPANION DIAGNOSTIC AGREEMENT by and between Merck Sharp & Dohme Research GmbHand ENDOCYTE, INC. (Filed With SEC on August 13, 2012)
- Obtain marketing approval of our phase 3-ready SMDC, EC145, for use in women with platinum-resistant ovarian cancer. We plan to initiate a randomized, controlled, double-blinded... (Filed With SEC on March 18, 2011)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on January 12, 2011)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on January 12, 2011)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on December 15, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on December 15, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on December 15, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on December 15, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on September 28, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on September 28, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on September 28, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on September 28, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on September 28, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on September 28, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on September 28, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on September 28, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on September 28, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on September 28, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on September 28, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on September 28, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on August 17, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on August 17, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on August 17, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on August 17, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on August 17, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on August 17, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on August 17, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on August 17, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on August 17, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on August 17, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on August 17, 2010)